Terms: = Brain cancer AND PDGFRB, JTK12, 5159, P09619, ENSG00000113721, PDGF-R-beta, PDGFR1, CD140B, PDGFR, CD140b AND Diagnosis
22 results:
1. Anlotinib alone or in combination with bevacizumab in the treatment of recurrent high-grade glioma: a prospective single-arm, open-label phase II trial.
Zhao S; Zhang M; Zhang Q; Wu J; Dai H
BMC Cancer; 2024 Jan; 24(1):6. PubMed ID: 38166698
[TBL] [Abstract] [Full Text] [Related]
2. Genetic alterations that deregulate RB and pdgfrA signaling pathways drive tumor progression in IDH2-mutant astrocytoma.
Tateishi K; Miyake Y; Nakamura T; Iwashita H; Hayashi T; Oshima A; Honma H; Hayashi H; Sugino K; Kato M; Satomi K; Fujii S; Komori T; Yamamoto T; Cahill DP; Wakimoto H
Acta Neuropathol Commun; 2023 Nov; 11(1):186. PubMed ID: 38012788
[TBL] [Abstract] [Full Text] [Related]
3. Clinical outcomes of patients with multiple courses of radiosurgery for brain metastases from non-small cell lung cancer.
Lee WJ; Choi JW; Kong DS; Seol HJ; Nam DH; Lee JI
Sci Rep; 2022 Jun; 12(1):10712. PubMed ID: 35739135
[TBL] [Abstract] [Full Text] [Related]
4. Efficacy of osimertinib plus bevacizumab in glioblastoma patients with simultaneous EGFR amplification and EGFRvIII mutation.
Cardona AF; Jaramillo-Velásquez D; Ruiz-Patiño A; Polo C; Jiménez E; Hakim F; Gómez D; Ramón JF; Cifuentes H; Mejía JA; Salguero F; Ordoñez C; Muñoz Á; Bermúdez S; Useche N; Pineda D; Ricaurte L; Zatarain-Barrón ZL; Rodríguez J; Avila J; Rojas L; Jaller E; Sotelo C; Garcia-Robledo JE; Santoyo N; Rolfo C; Rosell R; Arrieta O
J Neurooncol; 2021 Sep; 154(3):353-364. PubMed ID: 34498213
[TBL] [Abstract] [Full Text] [Related]
5. Splicing machinery dysregulation drives glioblastoma development/aggressiveness: oncogenic role of SRSF3.
Fuentes-Fayos AC; Vázquez-Borrego MC; Jiménez-Vacas JM; Bejarano L; Pedraza-Arévalo S; L-López F; Blanco-Acevedo C; Sánchez-Sánchez R; Reyes O; Ventura S; Solivera J; Breunig JJ; Blasco MA; Gahete MD; Castaño JP; Luque RM
Brain; 2020 Dec; 143(11):3273-3293. PubMed ID: 33141183
[TBL] [Abstract] [Full Text] [Related]
6. The TICking clock of EGFR therapy resistance in glioblastoma: Target Independence or target Compensation.
Saleem H; Kulsoom Abdul U; Küçükosmanoglu A; Houweling M; Cornelissen FMG; Heiland DH; Hegi ME; Kouwenhoven MCM; Bailey D; Würdinger T; Westerman BA
Drug Resist Updat; 2019 Mar; 43():29-37. PubMed ID: 31054489
[TBL] [Abstract] [Full Text] [Related]
7. Grade III meningioma with gastro-intestinal tract and brain metastases: case report and review of the literature.
Bender L; Lhermitte B; Carinato H; Baloglu S; Helali M; Cebula H; Antoni D; Noel G
World J Surg Oncol; 2019 Apr; 17(1):70. PubMed ID: 30992070
[TBL] [Abstract] [Full Text] [Related]
8. Longitudinal heterogeneity in glioblastoma: moving targets in recurrent versus primary tumors.
Schäfer N; Gielen GH; Rauschenbach L; Kebir S; Till A; Reinartz R; Simon M; Niehusmann P; Kleinschnitz C; Herrlinger U; Pietsch T; Scheffler B; Glas M
J Transl Med; 2019 Mar; 17(1):96. PubMed ID: 30894200
[TBL] [Abstract] [Full Text] [Related]
9. A comprehensive analysis of factors related to carmustine/bevacizumab response in recurrent glioblastoma.
Cardona AF; Rojas L; Wills B; Ruiz-Patiño A; Abril L; Hakim F; Jiménez E; Useche N; Bermúdez S; Mejía JA; Ramón JF; Carranza H; Vargas C; Otero J; Archila P; Rodríguez J; Rodríguez J; Behaine J; González D; Jacobo J; Cifuentes H; Feo O; Penagos P; Pineda D; Ricaurte L; Pino LE; Vargas C; Marquez JC; Mantilla MI; Ortiz LD; Balaña C; Rosell R; Zatarain-Barrón ZL; Arrieta O
Clin Transl Oncol; 2019 Oct; 21(10):1364-1373. PubMed ID: 30798512
[TBL] [Abstract] [Full Text] [Related]
10. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
[TBL] [Abstract] [Full Text] [Related]
11. Copy number alterations determined by single nucleotide polymorphism array testing in the clinical laboratory are indicative of gene fusions in pediatric cancer patients.
Busse TM; Roth JJ; Wilmoth D; Wainwright L; Tooke L; Biegel JA
Genes Chromosomes Cancer; 2017 Oct; 56(10):730-749. PubMed ID: 28597942
[TBL] [Abstract] [Full Text] [Related]
12. Concurrent radiotherapy and intrathecal methotrexate for treating leptomeningeal metastasis from solid tumors with adverse prognostic factors: A prospective and single-arm study.
Pan Z; Yang G; He H; Zhao G; Yuan T; Li Y; Shi W; Gao P; Dong L; Li Y
Int J Cancer; 2016 Oct; 139(8):1864-72. PubMed ID: 27243238
[TBL] [Abstract] [Full Text] [Related]
13. Pediatric Targeted Therapy: Clinical Feasibility of Personalized Diagnostics in Children with Relapsed and Progressive Tumors.
Selt F; Deiß A; Korshunov A; Capper D; Witt H; van Tilburg CM; Jones DT; Witt R; Sahm F; Reuss D; Kölsche C; Ecker J; Oehme I; Hielscher T; von Deimling A; Kulozik AE; Pfister SM; Witt O; Milde T
Brain Pathol; 2016 Jul; 26(4):506-16. PubMed ID: 26445087
[TBL] [Abstract] [Full Text] [Related]
14. Expression profiling of angiogenesis-related genes in brain metastases of lung cancer and melanoma.
Ilhan-Mutlu A; Siehs C; Berghoff AS; Ricken G; Widhalm G; Wagner L; Preusser M
Tumour Biol; 2016 Jan; 37(1):1173-82. PubMed ID: 26277786
[TBL] [Abstract] [Full Text] [Related]
15. Molecular stereotactic biopsy technique improves diagnostic accuracy and enables personalized treatment strategies in glioma patients.
Eigenbrod S; Trabold R; Brucker D; Erös C; Egensperger R; La Fougere C; Göbel W; Rühm A; Kretzschmar HA; Tonn JC; Herms J; Giese A; Kreth FW
Acta Neurochir (Wien); 2014 Aug; 156(8):1427-40. PubMed ID: 24792966
[TBL] [Abstract] [Full Text] [Related]
16. H3.3 G34R mutations in pediatric primitive neuroectodermal tumors of central nervous system (CNS-PNET) and pediatric glioblastomas: possible diagnostic and therapeutic implications?
Gessi M; Gielen GH; Hammes J; Dörner E; Mühlen AZ; Waha A; Pietsch T
J Neurooncol; 2013 Mar; 112(1):67-72. PubMed ID: 23354654
[TBL] [Abstract] [Full Text] [Related]
17. Quantitative analysis of vessels with smooth muscle layer in astrocytic tumors: correlation with histological grade and prognostic significance.
Sato S; Sato Y; Hatakeyama K; Marutsuka K; Yamashita A; Takeshima H; Asada Y
Histol Histopathol; 2011 Apr; 26(4):497-504. PubMed ID: 21360443
[TBL] [Abstract] [Full Text] [Related]
18. Early surgical intervention in adult patients with ganglioglioma is associated with improved clinical seizure outcomes.
Yang I; Chang EF; Han SJ; Barry JJ; Fang S; Tihan T; Barbaro NM; Parsa AT
J Clin Neurosci; 2011 Jan; 18(1):29-33. PubMed ID: 20961765
[TBL] [Abstract] [Full Text] [Related]
19. EGFR-targeted therapy in malignant glioma: novel aspects and mechanisms of drug resistance.
Lo HW
Curr Mol Pharmacol; 2010 Jan; 3(1):37-52. PubMed ID: 20030624
[TBL] [Abstract] [Full Text] [Related]
20. Primary and metastatic high-grade pleomorphic sarcoma/malignant fibrous histiocytoma of the gastrointestinal tract: an approach to the differential diagnosis in a series of five cases with emphasis on myofibroblastic differentiation.
Agaimy A; Gaumann A; Schroeder J; Dietmaier W; Hartmann A; Hofstaedter F; Wünsch PH; Mentzel T
Virchows Arch; 2007 Nov; 451(5):949-57. PubMed ID: 17874130
[TBL] [Abstract] [Full Text] [Related]
[Next]
